{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:07:36Z","timestamp":1761584856301,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.atherosclerosissup.2019.08.040","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T11:37:47Z","timestamp":1575632267000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus"],"prefix":"10.1016","volume":"40","author":[{"given":"Roman N.","family":"Rodionov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Jarzebska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annett","family":"Rexin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sradnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Brilloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Martens-Lobenhoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie M.","family":"Bode-B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Todorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Hohenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1681\/ASN.V11171","article-title":"Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy","volume":"11","author":"Veelken","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.V83487","article-title":"Diabetic nephropathy","volume":"8","author":"Ibrahim","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1590\/S0004-27302008000300004","article-title":"Early detection of diabetic nephropathy","volume":"52","author":"Murussi","year":"2008","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-5996-6-17","article-title":"Nitric oxide system and diabetic nephropathy","volume":"6","author":"Dellamea","year":"2014","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib5","first-page":"2842S","article-title":"Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the \"l-arginine paradox\" and acts as a novel cardiovascular risk factor","volume":"134","author":"Boger","year":"2004","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm1543","article-title":"Disruption of methylarginine metabolism impairs vascular homeostasis","volume":"13","author":"Leiper","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.287.11.1420","article-title":"Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor","volume":"287","author":"Stuhlinger","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1210\/jc.2006-2643","article-title":"Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations","volume":"92","author":"Altinova","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(01)02063-X","article-title":"Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus","volume":"88","author":"Abbasi","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc07-0019","article-title":"Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes","volume":"30","author":"Krzyzanowska","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib11","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2337\/dc07-1138","article-title":"Plasma asymmetric dimethylarginine (adma) is associated with retinopathy in type 2 diabetes","volume":"30","author":"Malecki","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib12","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc09-0816","article-title":"Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines","volume":"32","author":"Abhary","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/ndt\/gfn716","article-title":"Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes","volume":"24","author":"Hanai","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2337\/dc07-1762","article-title":"Plasma concentration of asymmetric dimethylarginine (adma) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy","volume":"31","author":"Lajer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/diacare.27.3.765","article-title":"Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes","volume":"27","author":"Tarnow","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.mnh.0000222701.22583.e8","article-title":"Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?","volume":"15","author":"Zoccali","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0140-6736(92)90865-Z","article-title":"Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure","volume":"339","author":"Vallance","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib18","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2005010076","article-title":"Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach","volume":"16","author":"Ravani","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib19","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/j.1523-1755.2005.00680.x","article-title":"Plasma asymmetric dimethylarginine (adma) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (svcam-1) concentration in patients with mild-to-moderate renal failure","volume":"68","author":"Nanayakkara","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/01.CIR.0000105764.22626.B1","article-title":"Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans","volume":"109","author":"Kielstein","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchromb.2012.07.021","article-title":"Quantification of l-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry","volume":"904","author":"Martens-Lobenhoffer","year":"2012","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib23","doi-asserted-by":"crossref","first-page":"F1299","DOI":"10.1152\/ajprenal.00254.2009","article-title":"Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and tgf-beta activation","volume":"297","author":"Daniel","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib24","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib26","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.2337\/diabetes.51.10.3083","article-title":"Podocyte number in normotensive type 1 diabetic patients with albuminuria","volume":"51","author":"White","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","article-title":"Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy","volume":"55","author":"Susztak","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib28","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1681\/ASN.2009070721","article-title":"Mouse models of diabetic nephropathy","volume":"20","author":"Brosius","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.exer.2009.09.004","article-title":"Prmt-1 and ddahs-induced adma upregulation is involved in ros- and ras-mediated diabetic retinopathy","volume":"89","author":"Chen","year":"2009","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/dmrr.662","article-title":"Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells","volume":"23","author":"Wang","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lfs.2004.10.062","article-title":"Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes","volume":"77","author":"Xiong","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ndt\/gfn630","article-title":"Involvement of asymmetric dimethylarginine (adma) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy","volume":"24","author":"Shibata","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db06-1772","article-title":"Expression of ng,ng-dimethylarginine dimethylaminohydrolase and protein arginine n-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin ii receptor blockers","volume":"57","author":"Onozato","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib34","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.2337\/diabetes.54.11.3282","article-title":"Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation","volume":"54","author":"Palm","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bjp.0702298","article-title":"Accelerated intimal hyperplasia and increased endogenous inhibitors for no synthesis in rabbits with alloxan-induced hyperglycaemia","volume":"126","author":"Masuda","year":"1999","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2019.08.040_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/pedi.12384","article-title":"Osteoprotegerin, rankl, adma, and fetuin-a serum levels in children with type i diabetes mellitus","volume":"18","author":"Chrysis","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1507\/endocrj.EJ14-0521","article-title":"Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children","volume":"62","author":"Takaya","year":"2015","journal-title":"Endocr J"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/jpem-2014-0083","article-title":"Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin","volume":"28","author":"Krebs","year":"2015","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib39","first-page":"137","article-title":"[asymmetric dimethylarginine (adma) in children with diabetes type 1]","volume":"16","author":"Glowinska-Olszewska","year":"2010","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib40","first-page":"179","article-title":"Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1","volume":"58","author":"Jehlicka","year":"2009","journal-title":"Physiol Res\/Academia Scientiarum Bohemoslovaca"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib41","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00726-015-2027-9","article-title":"The l-arginine\/no pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus","volume":"47","author":"Carmann","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.atherosclerosissup.2019.08.040_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.2004080648","article-title":"Mouse models of diabetic nephropathy","volume":"16","author":"Breyer","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568819300637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568819300637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:01:50Z","timestamp":1761584510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568819300637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"alternative-id":["S1567568819300637"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.040","relation":{},"ISSN":["1567-5688"],"issn-type":[{"type":"print","value":"1567-5688"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2019.08.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}